# EDGAR Filing Document

**Accession Number:** 0001735944
**File Stem:** 0000875320-26-000129
**Filing Date:** 2026-3
**Character Count:** 8803
**Document Hash:** 0bb034afde11deda2a59a54e596b564a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000875320-26-000129.hdr.sgml**: 20260303

**ACCESSION NUMBER**: 0000875320-26-000129

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260227

**FILED AS OF DATE**: 20260303

**DATE AS OF CHANGE**: 20260303

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Kewalramani Reshma
- **CENTRAL INDEX KEY:** 0001735944

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19319
- **FILM NUMBER:** 26715136

**MAIL ADDRESS:**
- **STREET 1:** C/O VERTEX PHARMACEUTICALS, INC.
- **STREET 2:** 50 NORTHERN AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VERTEX PHARMACEUTICALS INC / MA
- **CENTRAL INDEX KEY:** 0000875320
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043039129
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 50 NORTHERN AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 6173416393

**MAIL ADDRESS:**
- **STREET 1:** 50 NORTHERN AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Kewalramani Reshma<br><sub>(Last) (First) (Middle)</sub><br>C/O VERTEX PHARMACEUTICALS INCORPORATED<br>50 NORTHERN AVENUE<br><sub>(Street)</sub><br>BOSTON, MA 02210<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-27 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CEO & President_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>VERTEX PHARMACEUTICALS INC / MA [ VRTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-02-27 |  | S<sup>(1)</sup> |  | 400 | D | 479.75<sup>(2)(3)</sup> | 137878 | D |  |
| Common Stock | 2026-02-27 |  | S<sup>(1)</sup> |  | 120 | D | 481.50<sup>(2)(4)</sup> | 137758 | D |  |
| Common Stock | 2026-02-27 |  | S<sup>(1)</sup> |  | 240 | D | 482.84<sup>(2)(5)</sup> | 137518 | D |  |
| Common Stock | 2026-02-27 |  | S<sup>(1)</sup> |  | 2510 | D | 487.13<sup>(2)(6)</sup> | 135008 | D |  |
| Common Stock | 2026-02-27 |  | S<sup>(1)</sup> |  | 3278 | D | 488.27<sup>(2)(7)</sup> | 131730 | D |  |
| Common Stock | 2026-02-27 |  | S<sup>(1)</sup> |  | 460 | D | 489.32<sup>(2)(8)</sup> | 131270 | D |  |
| Common Stock | 2026-02-27 |  | S<sup>(1)</sup> |  | 2725 | D | 490.54<sup>(2)(9)</sup> | 128545 | D |  |
| Common Stock | 2026-02-27 |  | S<sup>(1)</sup> |  | 949 | D | 491.30<sup>(2)(10)</sup> | 127596 | D |  |
| Common Stock | 2026-02-27 |  | S<sup>(1)</sup> |  | 2520 | D | 493.29<sup>(2)(11)</sup> | 125076 | D |  |
| Common Stock | 2026-02-27 |  | S<sup>(1)</sup> |  | 3498 | D | 494.33<sup>(2)(12)</sup> | 121578 | D |  |
| Common Stock | 2026-02-27 |  | S<sup>(1)</sup> |  | 15580 | D | 495.38<sup>(2)(13)</sup> | 105998 | D |  |
| Common Stock | 2026-02-27 |  | S<sup>(1)</sup> |  | 5995 | D | 496.16<sup>(2)(14)</sup> | 100003 | D |  |
| Common Stock | 2026-02-27 |  | S<sup>(1)</sup> |  | 1725 | D | 496.95<sup>(2)(15)</sup> | 98278 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025.

(2) Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

(3) Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76).

(4) Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51).

(5) Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85).

(6) Open market sales reported on this line occurred at a weighted average price of $487.13  (range $486.64 to $487.55).

(7) Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56).

(8) Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79).

(9) Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01).

(10) Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85).

(11) Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77).

(12) Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75).

(13) Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78).

(14) Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74).

(15) Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17).

**Signature:** /s/ Christiana Stevenson, Attorney-in-Fact  
**Date:** 2026-03-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**